247 related articles for article (PubMed ID: 16613565)
1. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis.
Escribano L; Akin C; Castells M; Schwartz LB
Inflamm Allergy Drug Targets; 2006 Jan; 5(1):61-77. PubMed ID: 16613565
[TBL] [Abstract][Full Text] [Related]
2. Mastocytosis: current concepts in diagnosis and treatment.
Escribano L; Akin C; Castells M; Orfao A; Metcalfe DD
Ann Hematol; 2002 Dec; 81(12):677-90. PubMed ID: 12483363
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
4. Mastocytosis: mediator-related signs and symptoms.
Castells M; Austen KF
Int Arch Allergy Immunol; 2002 Feb; 127(2):147-52. PubMed ID: 11919427
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis.
Kurosawa M; Amano H; Kanbe N; Akimoto S; Takeuchi Y; Yamashita T; Hashimoto T; Kurimoto F; Miyachi Y
J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 2):S25-32. PubMed ID: 9440541
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.
Horny HP; Valent P
Leuk Res; 2001 Jul; 25(7):543-51. PubMed ID: 11377679
[TBL] [Abstract][Full Text] [Related]
7. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val.
Jordan JH; Fritsche-Polanz R; Sperr WR; Mitterbauer G; Födinger M; Schernthaner GH; Christian Bankl H; Gebhart W; Chott A; Lechner K; Valent P
Leuk Res; 2001 Jul; 25(7):627-34. PubMed ID: 11377687
[TBL] [Abstract][Full Text] [Related]
8. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.
Valent P; Sperr WR; Samorapoompichit P; Geissler K; Lechner K; Horny HP; Bennett JM
Leuk Res; 2001 Jul; 25(7):595-602. PubMed ID: 11377685
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
Valent P; Sperr WR; Schwartz LB; Horny HP
J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
[TBL] [Abstract][Full Text] [Related]
10. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
11. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
Castells M; Butterfield J
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1097-1106. PubMed ID: 30961835
[TBL] [Abstract][Full Text] [Related]
12. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.
Molderings GJ; Brettner S; Homann J; Afrin LB
J Hematol Oncol; 2011 Mar; 4():10. PubMed ID: 21418662
[TBL] [Abstract][Full Text] [Related]
13. Mast cells and mastocytosis.
Söderholm JD
Dig Dis; 2009; 27 Suppl 1():129-36. PubMed ID: 20203509
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular symptoms in patients with systemic mast cell activation disease.
Kolck UW; Haenisch B; Molderings GJ
Transl Res; 2016 Aug; 174():23-32.e1. PubMed ID: 26775802
[TBL] [Abstract][Full Text] [Related]
15. Mast cell mediators in allergic inflammation and mastocytosis.
Castells M
Immunol Allergy Clin North Am; 2006 Aug; 26(3):465-85. PubMed ID: 16931289
[TBL] [Abstract][Full Text] [Related]
16. No relationship between histamine release measured as metabolite excretion in the urine, and serum levels of mast cell specific tryptase in mastocytosis.
Granerus G; Lönnqvist B; Roupe G
Agents Actions; 1994 Jun; 41 Spec No():C127-8. PubMed ID: 7526641
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.
Valent P; Escribano L; Parwaresch RM; Schemmel V; Schwartz LB; Sotlar K; Sperr WR; Horny HP
Int Arch Allergy Immunol; 1999 Sep; 120(1):1-7. PubMed ID: 10529583
[TBL] [Abstract][Full Text] [Related]
18. Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study.
Horny HP; Greschniok A; Jordan JH; Menke DM; Valent P
J Clin Pathol; 2003 Feb; 56(2):103-6. PubMed ID: 12560387
[TBL] [Abstract][Full Text] [Related]
19. Mast Cell Activation Syndrome.
Frieri M
Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
[TBL] [Abstract][Full Text] [Related]
20. Current approaches to the diagnosis and treatment of systemic mastocytosis.
Bains SN; Hsieh FH
Ann Allergy Asthma Immunol; 2010 Jan; 104(1):1-10; quiz 10-2, 41. PubMed ID: 20143640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
